Introduction
The addition of pharmacological doses of all-trans retinoic acid (ATRA) to chemotherapy has clearly revolutionized the clinical outcome of acute promyelocytic leukemia (APL) [1] . In vitro observations have also suggested that exposure to ATRA may sensitize both non-APL acute myeloid leukemia (AML) cell lines and primary cells to cytotoxic agents, such as Ara-C and anthracyclines, thereby increasing either differentiation or apoptosis, by down-regulation of Bcl2 and related proteins [1, 2] . Based upon these preclinical data demonstrating a synergistic effect of ATRA combined with chemotherapy, several clinical studies, including large randomized trials (Table S1) , have investigated the impact of adding ATRA to either remission induction chemotherapy or lower intensity regimens in patients with non-APL AML, but these studies have overall yielded inconsistent and conflicting results [1] . However, making direct comparisons between studies reporting discrepant clinical outcomes is difficult because of different patient age, leukemia characteristics, chemotherapy regimens and schedule of ATRA administration [1, [3] [4] [5] .
Low-dose Ara-C (LDAC) has been widely used with different schedules within phase II trials for elderly patients with AML considered unfit for intensive chemotherapy, obtaining complete remission (CR) in about 20% of cases, but with unsatisfactory two-year overall survival (OS) rates of approximately 10% [2] . LDAC has become the prototype for low-intensity chemotherapy after the randomized trial by Burnett et al. in which LDAC produced higher CR rate (18% vs. 1%) and better OS, when compared to palliative hydroxyurea [2] . However, median OS (5 months) was still poor for the LDAC cohort and survival advantage was not recorded for patients with adverse cytogenetics, in whom CR was never achieved. Moreover, in this study, the addition of ATRA to either of the treatment arms had no beneficial effect on OS [2] . Conversely, some previous studies had shown positive effects of combining ATRA with LDAC, also in poor risk patients with AML unsuitable for aggressive chemotherapy [6, 7] . Venditti et al. reported a high CR rate (48%) in 33 patients with poor prognosis AML, either at disease onset or relapsed/refractory [6] . Moreover, in the retrospective study on 28 patients by Di Febo et al., a significant improvement in OS was observed, compared with LDAC alone, although the combination treatment did not increase the CR rate [7] . Unfortunately, none of these studies focused on the presence of NPM1 gene mutations in leukemic cells [2, 6, 7] . Of note, retrospective molecular examinations on archival samples would potentially be of interest in order to precisely evaluate the clinical impact of ATRA combined with LDAC in specific molecular subgroups of unfit patients with AML [2, 6, 7] .
Case Reports
We report on three elderly patients affected with cytogenetically normal NPM1-mutated AML, without FLT3 and IDH1-R132 mutations, considered unfit for intensive chemotherapy, because of advanced age and/or comorbidities (Table 1) , who received moderate intensity treatment consisting of LDAC combined with ATRA. Patients have been hospitalized at AML diagnosis and received the first treatment course as inpatients. In details, LDAC 20 mg was administered subcutaneously twice daily on days 1-10, while ATRA 45 mg/m 2 /day was given orally for 60 days (from day +3 to +62). Patients 1, 2, and 3 have spent 24, 22, and 20 days in the hospital, respectively, thereafter they were discharged and safely managed in an outpatient setting. Subsequent LDAC cycles have been administered, after intervals of 4 weeks, while each subsequent ATRA course has been started after 1 month interval (e.g., second ATRA course starting from day +3 of the fourth LDAC cycle). After two LDAC cycles combined with one ATRA course, morphologic CR was documented on bone marrow (BM) aspirate in patients 1 and 3, whereas in patient 2, BM aspirate was unfortunately not performed. However, in this latter patient, normal WBC and platelet counts, without circulating blasts, were obtained, with a concurrent reduction of RBC transfusion requirement. Unfortunately, on day +6 of the fourth LDAC cycle, disease progression was observed with WBC count 64.8 9 10
9 /L and 70% circulating blasts, Hb 8.1 g/dL, Plt count 12 9 10 9 /L. The patient died a few days later, 5 months since AML diagnosis. Patient 1 underwent nine LDAC cycles combined with three ATRA courses without experiencing any complication; then, treatment was withdrawn, while persisting morphologic CR. However, 9 months after therapy interruption, leukemia relapsed with circulating and BM blast counts 2% and 15%, respectively. Retreatment with the same previously administered cytotoxic regimen was attempted. The patient then received LDAC (four cycles) and ATRA (two courses) and 2 months after initiation of therapy, full hematologic recovery was documented, concurrently with a reduction in BM blast count (5-10%). However, the patient subsequently suffered from pneumonia, sinusitis and hematuria secondary to bladder mucosal lesions, with successive occurrence of pancytopenia, and died 8 and 26 months after relapse and first AML diagnosis, respectively. Patient 3 showed transient grade 2 gastrointestinal toxicity during first LDAC cycle, without any further relevant toxicity, until leukemia relapse was documented while receiving the tenth LDAC and third ATRA courses, respectively. He died a few weeks later, 11 months since initial diagnosis. Unfortunately, we have not measured quality of life (QoL) with validated instruments in these three patients.
Other AML patients, in particular with NPM1 wild type, unfit for intensive chemotherapy, have not been treated with the same therapeutic strategy (LDAC + ATRA) at our Institution.
Discussion
Several experimental evidence supports the modulation of the retinoic acid-signaling pathway as a potential target for therapy in NPM1-mutated AML [8] [9] [10] [11] [12] . Earlier in vitro studies by Martelli et al. showed that pharmacological doses of ATRA induced cell cycle arrest and apoptosis in both NPM1-mutated cell line OCI-AML3 and primary leukemic cells propagated in NOD-SCID mice, by selectively down-regulating the NPM1 mutant protein at post-transcriptional level [8] . Moreover, Kutny et al. demonstrated that NPM1-mutated AML cells may also be susceptible, in vitro, to the pro-differentiating properties of ATRA [9] . Further in vitro findings also suggested that targeted depletion of NPM1 protein may selectively sensitize NPM1-mutated AML cells to Ara-C and ATRA [10] . Of note, it has recently been reported that exposure of NPM1-mutated AML cells to ATRA and arsenic trioxide (ATO) induces selective proteasome-mediated degradation of NPM1 mutant protein accompanied by nucleolar redistribution of wild-type NPM1, reversal of the characteristic disorganization of PML bodies and pronounced apoptosis and/or differentiation [11, 12] . Strikingly, NPM1 mutant protein down-regulation by ATRA/ATO was shown to potentiate response to daunorubicin [11] . Available information on the clinical use of ATRA in adjunct to other antileukemic treatments in NPM1-mutated patients with AML is summarized in Table 2 [3-5, 12 -18] . Interestingly, in a retrospective biomarker analysis within the randomized HD98B trial, Schlenk et al. showed that the addition of ATRA to conventional chemotherapy, including etoposide, significantly improved event-free survival and OS only in the subgroup of elderly patients with NPM1-mutated AML without FLT3-ITD mutation [3] . Furthermore, preliminary data from the prospective randomized treatment trial AMLSG 07-04 for younger patients with AML seem to confirm the results obtained in elderly patients [18] . In details, the beneficial effect of ATRA on OS in the whole cohort could be attributed to patients with favorable risk AML, including NPM1-mutated AML in the absence of FLT3-ITD [18] . Intriguingly, biological observations from these series suggested that repressor activity on retinoic acid signaling induced by high-PRAME levels may be overcome by the addition of ATRA [19] . Conversely, the randomized MRC AML12 trial for patients AML <60 years of age did not identify any molecular subgroup, defined by mutations in NPM1, FLT3, CEBPA genes, likely to derive a significant survival benefit from the addition of ATRA to aggressive chemotherapy [4] . Consistently, in an analysis stratified by etoposide addition and NPM1/FLT3 mutational status, there was no significant improvement in clinical outcomes by the addition of ATRA to intensive chemotherapy for any subgroup of older patients enrolled in NCRI AML16 trial [15] . Moreover, Nazha et al. observed that the addition of ATRA to chemotherapy did not affect overall outcome of patients with AML regardless of NPM1 mutational status [5] . However, it should be noted that limitations of this study include the small sample size (20 NPM1-mutated patients with AML) and that other gene mutations, such as FLT3-ITD, have not been investigated in this retrospective analysis [5] . Overall, there is currently no consensus as to whether the addition of ATRA to chemotherapy improves the clinical outcome of NPM1-mutated patients with AML (Table 2 ) [1, 3-5, 15, 18] . Of note, dosing schedule and timing of ATRA administration, namely before, simultaneously or after exposure to conventional chemotherapy, may be relevant to explain discrepancies observed in different series [3-5, 15, 18] . Of interest, in vitro experiments indicated that synergistic effects on cell viability were only observed when ATRA was given after exposure to cytotoxic drugs [3] . Indeed, in our three patients, such as in AustrianGerman trials, ATRA administration has been started a few days after chemotherapy, a timepoint when leukemic cells have already been exposed to a significant cytotoxic effect [3, 18] . However, in addition to the potential efficacy of LDAC in association with ATRA, we acknowledge that the relatively favorable clinical outcome observed in two of our three elderly patients with AML, may also have been attributed to the less aggressive molecular features, namely NPM1 gene mutation without FLT3 gene mutations, documented in leukemic cells [20] [21] [22] [23] .
Despite the huge amount of data, although conflicting, regarding NPM1-mutated patients with AML treated with ATRA combined with intensive chemotherapy, scanty information is so far available on the association of ATRA and LDAC in this molecular subgroup of patients, when elderly and fragile [14] . Based upon our clinical observations, we suggest that the combination of LDAC and ATRA may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated AML without FLT3 mutations, a relatively good prognosis AML. Although IDH1-R132 mutation has not been documented in our patients, it should be noted that ATRA at clinically achievable doses has recently been shown to markedly enhance terminal granulocytic differentiation in vitro, in either AML cell lines or primary patient samples carrying mutant IDH1 [24] . Moreover, a potent antileukemic effect of ATRA was observed in the presence of IDH1-R132H mutation in a xenograft mouse model, suggesting that IDH1-R132 mutation could be a valuable biomarker to select patients with AML for ATRA treatment [24] .
Perspective randomized clinical trials are warranted to compare LDAC alone versus LDAC combined with ATRA and/or ATO, in order to clarify the exact role of such treatments in these selected genetic subsets of fragile patients [25] . In addition to the assessment of the efficacy in terms of response rates and survival, further endpoints, Seventy patients with NK-AML who were enrolled in a previous phase II randomized clinical trial and had stored BM samples for NPM1 mutation analysis. Twenty (29%) patients had NPM1 mutation. Among them, seven patients received ATRA + chemotherapy.
Patients were randomly assigned to receive, as CR rate in patients with NPM1 mutation was 71% and 69%, with or without ATRA, respectively. Median OS, EFS, RFS for the entire group were 11.5, 7, and 11.5 months, respectively.
The addition of ATRA to induction chemotherapy did not affect CR rate, OS, EFS, and RFS of patients with NK and NPM1 mutation. A PP analysis revealed higher probability for NPM1-mutated AML patients treated with ATRA to achieve a CR, with longer EFS. Explorative analysis in all patients on OS revealed a benefit for patients treated with ATRA compared to those who have not received ATRA (ITT, P = 0.09; PP, P = 0.01).
The beneficial effect of ATRA on OS in the whole cohort of younger patients could be attributed to patients with ELN-favorable risk including core-binding factor AML, AML with CEBPAdm and NPM1-mutated AML in the absence of FLT3-ITD. such as transfusion requirements, achievement of transfusion independence, number and duration of hospitalizations per patient year, are actually recognized as extremely relevant, especially in clinical trials investigating moderate intensity treatments [26] . Moreover, QoL parameters and other patient-reported outcomes, assessed with validated instruments, should increasingly be incorporated as secondary endpoints in clinical studies for patients with AML [27] . patients. The combination is unlikely to be curative alone, but may be part of a broader therapeutic strategy.
ATRA, all-trans retinoic acid; AML, acute myeloid leukemia; CR, complete remission; BM, bone marrow; G-CSF, granulocyte-colony stimulating factor; WBC, white blood cell; EFS, event-free survival; OS, overall survival; DFS, disease-free survival; MDS; myelodysplastic syndrome; VPA, valproic acid; CRi, complete remission with incomplete blood count recovery; ORR, overall response rate; ORR, overall response rate; PB, peripheral blood; RFS, relapse-free survival; NK, normal karyotype; HSCT, hematopoietic stem cell transplant; PP, per protocol; ITT, intention to treat; ELN, European LeukemiaNet; ATO, arsenic trioxide; IA, invasive aspergillosis.
